Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. The company was incorporated in 2016 and is based in Taichung, Taiwan.
Stock data | 2024 | Change |
---|---|---|
Price | $5.30 | N/A |
Market Cap | $388.59M | N/A |
Shares Outstanding | 73.34M | N/A |
Employees | 0 | N/A |